title: Medical risk factor treatment in peripheral arterial disease. Need for further improvement.
abstract: OBJECTIVE
  Risk factors for development of peripheral arterial disease (PAD) are the same as for atherosclerotic coronary or precerebral disease, and patients with PAD have a high prevalence of concomitant atherosclerotic disease in coronary and precerebral arteries. However, these patients are still less likely to receive appropriate pharmacological secondary prevention than patients with coronary artery disease. The aim of this study was to evaluate the treatment of risk factors for patients undergoing open or endovascular surgery for PAD in our vascular department.
  
  
  METHODS
  We evaluated pharmacological treatment, lipid levels, blood pressures (BP), and smoking habits one month postoperatively in 953 patients (age [mean ± SD] 71±11 years, 524 [55%] men) undergoing open or endovascular surgical interventions for PAD.
  
  
  RESULTS
  We found that 89% of patients received statins and 98% received either platelet aggregation inhibitors or anticoagulants at the one month follow-up. Four hundred nineteen (70%) patients had achieved target level <4.5 mmol/L for s-total cholesterol, and 394 (67%) target level <2.5 mmol/L for s-LDL cholesterol. BP (mean ± SD) was 144±22/76±12 mmHg, systolic and diastolic target BPs (<140 mmHg and <90 mmHg, respectively) were achieved in 482 (51%) and 887 (95%) patients, respectively. The proportion of active smokers had been reduced from 41% preoperatively to 24% at the one month follow-up (P<0.0001).
  
  
  CONCLUSIONS
  Even though our practice has improved, there is still room for better follow-up of pharmacological risk factor treatment in PAD patients.
authors.affiliation: Vascular Center, Skåne University Hospital, Malmö, Sweden. alaa.alhadad@gmail.com
authors.forename: A
authors.initials: A
authors.lastname: Alhadad
authors.forename: C
authors.initials: C
authors.lastname: Wictorsson
authors.forename: H
authors.initials: H
authors.lastname: Alhadad
authors.forename: B
authors.initials: B
authors.lastname: Lindblad
authors.forename: A
authors.initials: A
authors.lastname: Gottsäter
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood; D001794:Blood Pressure / Q000187:drug effects; D016009:Chi-Square Distribution; D002784:Cholesterol / Q000097:blood; D057510:Endovascular Procedures; D005260:Female; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D058729:Peripheral Arterial Disease / Q000097:blood / Q000453:epidemiology / Q000503:physiopathology / Q000601:surgery*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D010818:Practice Patterns, Physicians' / Q000706:statistics & numerical data; D012307:Risk Factors; D055502:Secondary Prevention / Q000379:methods; D016540:Smoking Cessation; D013548:Sweden / Q000453:epidemiology; D013997:Time Factors; D016896:Treatment Outcome; D014656:Vascular Surgical Procedures
chemical_list: D000925:Anticoagulants; D000959:Antihypertensive Agents; D015415:Biomarkers; D000960:Hypolipidemic Agents; D010975:Platelet Aggregation Inhibitors; D002784:Cholesterol